Couldn't agree more. The market wants to see something that brings OSX some funds to quell its immediate balance sheet concerns. Meanwhile the recognition of OSX's products in academic and research circles says volumes on its science. That this stock did not propel upwards on the Zimmer Biomet distribution deal astonishes me.
That will raise the 10 countries across EMEA, Australia, and NZ in which it presently markets its craniofacial products, to 24 countries initially and then potentially up to 162 countries. There will be a lag of course in sales of course, but I expect them to quickly double. This is not a $5 million mkt cap company even with a massive execution risk discount applied.
OSX Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)